Hostname: page-component-76fb5796d-x4r87 Total loading time: 0 Render date: 2024-04-26T08:34:16.333Z Has data issue: false hasContentIssue false
  • English
  • Français

The Second Canadian Conference on Multiple Sclerosis

Published online by Cambridge University Press:  18 September 2015

Brian G. Weinshenker  and
Robert Nelson
Brian G. Weinshenker*
Affiliation:
Division of Neurology, University of Ottawa, Ottawa
Robert Nelson
Affiliation:
Division of Neurology, University of Ottawa, Ottawa
*
Room 6365, Ottawa General Hospital, 501 Smyth Road, Ottawa, Ontario, Canada KIH 8L6
Rights & Permissions [Opens in a new window]

Abstract:

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.

The epidemiology of multiple sclerosis (MS) and the planning and interpretation of clinical therapeutic trials were the subjects of a symposium on MS held on June 13, 1989. Several speakers addressed whether MS is a genetic or an environmental disease. An environmental trigger would resolve the relatively low penetrance of the disease in susceptible individuals, although the alternative hypothesis that MS is a multigenic disease would also account for this observation. Clinical trials have to date failed to confirm the efficacy of any immunosuppressive or other agent in the management of progressive MS. Magnetic resonance imaging (MRI) appears to be highly sensitive for monitoring the activity of MS. Preliminary evidence suggests that MRI activity correlates with longitudinal clinical assessments of disability. Immunologic tests, while valuable in determining pathophysiology of MS, have not been strongly correlated with clinical outcome.

Type
Symposium Summary
Information
Canadian Journal of Neurological Sciences , Volume 17 , Issue 1 , February 1990 , pp. 53 - 60
Copyright
Copyright © Canadian Neurological Sciences Federation 1990

References

REFERENCES

1.Hader, WJ. Prevalence of multiple sclerosis in Saskatoon. Can Med Assoc J 1982; 127: 295–297.Google ScholarPubMed
2.Irvine, DG, Schieffer, HB, Hader, WJ. Geotoxicology of multiple sclerosis: the Henribourg, Saskatchewan cluster focus. Science of the Total Environment 1988; 77: 175–188.CrossRefGoogle ScholarPubMed
3.Sadovnick, AD, Bulman, D, Ebers, GC. Parent-child concordance in multiple sclerosis. Am J Hum Genet 1988; 43 (Suppl): A165.Google Scholar
4.Sadovnick, AD, Baird, PA, Ward, RH. Multiple sclerosis: updated risks for relatives. Am J Med Genet 1988; 29: 533–541.CrossRefGoogle ScholarPubMed
5.Sweeney, VP, Sadovnick, AD, Brandejs, V. Prevalence of multiple sclerosis in British Columbia. Can J Neurol Sci 1986; 13: 47–51.CrossRefGoogle ScholarPubMed
6.Sadovnick, AD, Paty, DW, Ebers, GC. Life expectancy and cause of death in multiple sclerosis. Neurology 1989; 39 (Suppl 1): 285.Google Scholar
7.Pryse-Phillips, WE. The incidence and prevalence of multiple sclerosis in Newfoundland and Labrador, 1960-1984. Ann Neurol 1986; 20(3): 323–328.CrossRefGoogle ScholarPubMed
8.Ebers, GC, Bulman, DE, Sadovnick, AD, et al. A population-based study of multiple sclerosis in twins. N Engl J Med 1986; 315: 1638–1642.CrossRefGoogle ScholarPubMed
9.Kinnunen, E, Koskenvuo, M, Kaprio, J, et al. Multiple sclerosis in a nationwide series of twins. Neurology 1987; 37: 1627–1629.CrossRefGoogle Scholar
10.Ebers, GC, Paty, DW, Stiller, CR, et al. HLA-typing in multiple sclerosis sibling pairs. Lancet 1982; 2: 88–90.CrossRefGoogle ScholarPubMed
11.Mackay, RP, Myrianthopoulos, NC. Multiple sclerosis in twins and their relatives. Arch Neurol Psych 1966; 15: 449–462.CrossRefGoogle ScholarPubMed
12.Kurtzke, JF, Hyllested, K. Multiple sclerosis in the Faroe Islands I. Clinical and epidemiological features. Ann Neurol 1979; 5: 6–21.CrossRefGoogle ScholarPubMed
13.Kurtzke, JF, Hyllested, K. Multiple sclerosis in the Faroe Islands II. Clinical update, transmission, and the nature of MS. Neurology 1985; 36: 307–328.Google Scholar
14.Kurtzke, JF, Hyllested, K. Multiple sclerosis in the Faroe Islands III. An alternative assessment of the three epidemics. Acta Neurol Scand 1987; 76: 317–339.CrossRefGoogle ScholarPubMed
15.Kurtzke, JF. Hyllested, K, Arbuckle, JD, et al. Multiple sclerosis in the Faroe Islands IV. The lack of a relationship between canine distemper and the epidemics of multiple sclerosis. Acta Neurol Scand 1988; 78: 484–500.CrossRefGoogle Scholar
16.Weinshenker, B, Rice, GPA. Retroviral disease of the nervous sytem. In: Kim, SE, ed. Myelination and Demyelination. New York: Plenum Publising 1989; 145–152.CrossRefGoogle Scholar
17.Roman, GC. Retrovirus associateci myelopathies. Arch Neurol 1987; 44: 659–663.CrossRefGoogle ScholarPubMed
18.Osarne, M, Matsumoto, M, Usuku, K, et al. Chronic progressive myelopathy associated with antibodies to human T-lymphotropic virus type I and adult T-cell leukemia like cells. Ann Neurol 1987; 21: 117–122.Google Scholar
19.Power, C, Weinshenker, BG, Dekaban, GA, Rice, GPA. HTLV-1 associated myelopathy in Canada. Clinical and diagnostic features. Can J Neurol Sci 1989; 16: 330–335.CrossRefGoogle Scholar
20.Koprowski, H, De Freitas, EC, Harper, ME, et al. Multiple sclerosis and human T-cell lymphotropic retrovirus. Nature 1986; 318: 154–160.CrossRefGoogle Scholar
21.Reddy, EP, Sandberg-Wollheim, M, Mettus, RV, et al. Amplification and molecular cloning of HTLV-1 sequences from DNA of multiple sclerosis patients. Science 1989; 243: 529–532.CrossRefGoogle ScholarPubMed
22.Greenberg, SJ, Ehrlich, GD, Abbott, MA, et al. Demonstration of retroviral sequences related to human T-cell leukemia/lymphoma virus, type I, in multiple sclerosis by gene amplification. Neurology 1989; 39 (Suppl 1): 381.Google Scholar
23.Hauser, SL, Dawson, DM, Lehrich, JR, et al. Intensive immunosuppression in progressive multiple sclerosis. N Engl J Med 1983; 308: 173–180.CrossRefGoogle ScholarPubMed
24.Nuwer, MR, Packwood, JW, Myers, LW, et al. Evoked potentials predict the clinical changes in a multiple sclerosis drug study. Neurology 1987; 37: 1754–1761.CrossRefGoogle Scholar
25.Khatri, BO, McQuillen, MP, Harrington, GJ, et al. Chronic progressive multiple sclerosis: double-blind controlled study of plasmapheresis in patients taking immunosuppressive drugs. Neurology 1985; 35: 312–319.CrossRefGoogle ScholarPubMed
26.Noseworthy, JH and the Canadian Cooperative Multiple Sclerosis Study Group. Concordance between examining neurologists on multiple sclerosis disability scales in a blinded, prospective clinical trial. Neurology 1988; 38 (Suppl 1): 195.Google Scholar
27.Noseworthy, JH, Vandervoort, MK, Hopkins, M, et al. A referendum on clinical trial research in multiple sclerosis: the opinion of the participants at the Jekyll Island Workshop. Neurology 1989; 39: 977–981.CrossRefGoogle Scholar
28.Weinshenker, BG, Ebers, GC. The natural history of multiple sclerosis. Can J Neurol Sci 1987; 14: 255–261.CrossRefGoogle ScholarPubMed
29.Weinshenker, BG, Bass, B, Rice, GPA, et al. The natural history of multiple sclerosis: a geographically based study I. Clinical course and disability. Brain 1989; 112: 133–146.CrossRefGoogle Scholar
30.Paty, DW. Magnetic resonance imaging in the assessment of disease activity in multiple sclerosis. Can J Neurol Sci 1988; 15: 266–272.Google ScholarPubMed
31.Paty, DW, Oger, JJF, Kastrukoff, LF, et al. MRI in the diagnosis of MS: a prospective study with comparison of clinical evaluation, evoked potentials, oligoclonal banding, and CT. Neurology 1988; 38: 150–185.Google Scholar
32.Isaac, C, Li, DKB, Grenton, M, et al. Multiple sclerosis: a serial study using MRI in relapsing patients. Neurology 1988; 38: 1511–1515.CrossRefGoogle ScholarPubMed
33.Willoughby, EW, Grochowski, E, Li, DKB, et al. Serial magnetic res-onance scanning in multiple sclerosis: a second prospective study in relapsing patients. Ann Neurol 1989; 25: 43–49.CrossRefGoogle Scholar
34.Koopmans, RA, Li, DKB, Oger, JJF, et al. Chronic progressive multiple sclerosis: serial magnetic resonance brain imaging over six months. Ann Neurol 1989; 26: 248–256.CrossRefGoogle ScholarPubMed
35.Hafler, DA, Fox, DA, Manning, ME, et al. In vivo activated T lymphocytes in the peripheral blood and cerebrospinal fluid of patients with multiple sclerosis. N Engl J Med 1985; 312: 1405–1411.CrossRefGoogle ScholarPubMed
36.Oger, J, Antel, J, Arnason, BGW. Effect of imuran therapy on in vitro immune function of MS patients. Ann Neurol 1982; 2: 177–181.CrossRefGoogle Scholar
37.Antel, JP, Arnason, BGW, Medof, ME. Supressor cell function in multiple sclerosis: correlation with clinical disease activity. Ann Neurol 1978; 5: 338–342.Google Scholar
38.Rose, LM, Ginsberg, AH, Rothstein, TL, et al. Selective loss of a subset of T helper cells in active multiple sclerosis. Proc Natl Acad Sci USA 1985; 82: 7389–7393.CrossRefGoogle ScholarPubMed
39.Freedman, MS, Blain, M, Antel, JP. Comparison of systemic and intrathecal immunoregulatory mechanisms. Neurology 1989; 39 (Suppl 1): 417.Google Scholar
40.Panitch, HS, Hirsch, RL, Schindler, J, et al. Treatment of multiple sclerosis with gamma interferon: exacerbations associated with activation of the immune system. Neurology 1987; 37: 1097–1102.Google ScholarPubMed
41.Bornstein, MB, Miller, A, Slagle, S, et al. A pilot trial of COP-1 in exacerbating remitting multiple sclerosis. N Engl J Med 1987; 317: 408–414.CrossRefGoogle ScholarPubMed